Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2023
Price :
$35
*
At a glance
- Drugs Lumateperone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Intra-Cellular Therapies
- 06 Mar 2023 Results of pooled analysis from NCT01499563, NCT02282761, NCT02469155 published in the Journal of Clinical Psychiatry
- 07 Jun 2021 Pooled analysis (study 005 [NCT01499563], study 301 [NCT02282761] and study 302 [NCT02469155]) published in the Intra-Cellular Therapies Media Release.
- 07 Jun 2021 According to an Intra-Cellular Therapies media release, a pooled analysis of 3 randomized, double-blind, placebo-controlled trials (study 005 [NCT01499563], study 301 [NCT02282761] and study 302 [NCT02469155]) was recently published online in International Clinical Psychopharmacology.